Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (MA.39 TAILOR RT)

Treatment agent: Radiotherapy
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / Canadian Cancer Trials Group
Location: Providence Queen of the Valley Medical Center, Napa, CA

Sermonix SMX-22-002 ELAINE 3

Treatment agent: Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation - Full Text View - ClinicalTrials.gov
Sponsor: Sermonix Pharmaceuticals Inc.
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with Stave IV advanced/ metastatic Hormone Receptor positive, HER2 negative breast cancer (Capitello 292)

Treatment agent: Capiversitib + CDK4/6 inhibitor + Fulvestrant
Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | ClinicalTrials.gov
Sponsor: Capitello
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with PD-L1 positive locally recurrent, inoperable, or metastatic triple negative breast cancer (Tropion Breast 05) Treatment agent: Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab

Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

Neo-adjuvant and adjuvant ( treatment study for participants with triple negative or hormone receptor low or HER2 negative breast cancer (Tropion Breast 04)

Treatment agent: Dato-DXd and Durvalumab
Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | ClinicalTrials.gov
Sponsor: Astra Zeneca
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of TDM1 and Placebo Compared with T-DM1 and Tucatinib

Treatment agent: T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | ClinicalTrials.gov
Sponsor: Alliance for Clinical Trials in Oncology
Location: Providence Cancer Center, Santa Rosa, CA

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Treatment agent: Durvalumab plus SoC chemo vs. SoC chemo alone
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | ClinicalTrials.gov
Sponsor: National Cancer Institute (NCI)
Location: Providence Cancer Center, Santa Rosa, CA

S2212, SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY

Treatment agent: SOC 6 cycles of Chemo/immunotherapy (Carboplatin/Docetaxel/ Pembro) VS Chemo/immunotherapy with pembro 8 cycles + 4 cycles of carbo/paclitaxel + 4 cycles of doxorubicin/cyclophosphamide
Physician: Dr Daniel Paul Mirda, MD | Medical Oncology in Napa | Providence Medical Group Sonoma
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: Study Details | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | ClinicalTrials.gov
Sponsor: SWOG Cancer Research Network
Location: Providence Queen of the Valley Medical Center, Napa, CA